

Exercise and Regulation of PI3K/Akt/mTOR and AMPK Pathways in Cancer: Molecular Mechanisms and Therapeutic Implications: A Narrative Review

Abeer Issa Mohammed¹, Ochilova Gulrux Saidovna², Davron Makhmudov³, Narkulova Sokhiba⁴, Istamov Mirmukhsinjon Bakhodirovich⁵, Goziyeva Shoista Sultonbekovna⁶, Qobilov Odiljon Rustamovich⁷, Niyozova Shaxnoza Xamoydinovna⁸, Izrailbekova Kamila Shavkatovna⁹, Achilova Ozoda Farkhodovna¹⁰, Berdikulova Nigina Mirsoliyevna¹¹, Ergasheva Zilolaxon Xasanboy Qizi¹², Azim Akbarzadehkhayavi^{13*}, Mohsen Mir^{14*}

¹Al-Manara College for Medical Sciences, University of Manara, Iraq, Advanced Medical and Dental Institute, University Sains Malaysia, Kepala Batas, Pulau Penang, Malaysia. ²Department of Clinical Pharmacology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara, Uzbekistan. ³Department of Children's Infectious Diseases, Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan. ⁴Department of Obstetrics and Gynecology N3, Samarkand State Medical University, Samarkand, Uzbekistan. ⁵Department of Psychiatry, Narcology and Medical Psychology, Bukhara State Medical Institute named after Abu Ali ibn Sino, Bukhara Uzbekistan. ⁶Department of Obstetrics and Gynecology No. 1, Faculty of Pediatrics, Andijan State Medical Institute, Uzbekistan. ⁷Department of Oncology, Pediatric Oncology, and Palliative Care, Tashkent State Medical University, Tashkent, Uzbekistan. ⁸Department of Oncology, Clinical Oncology, Oncohematology, and Radiation Oncology, Tashkent State Medical University, Tashkent, Uzbekistan. ⁹Department of Republican Oncology Center, Medical Oncologist (Chemotherapist), Tashkent, Uzbekistan. ¹⁰Department of Japanese Philology, Faculty of Oriental Languages, Samarkand State Institute of Foreign Languages, Uzbekistan. ¹¹Department of Japanese Philology, Faculty of Oriental Languages, Samarkand State Institute of Foreign Languages, Uzbekistan. ¹²Department of Food Technology and Engineering, Faculty of Food Technology and Management, International Institute of Food Technology and Engineering, Uzbekistan. ¹³Professor of Institute Pasteur of Iran in Department of Nanobiotechnology, Tehran, Iran. ¹⁴Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Abstract

Overview: Dysregulation of the PI3K/Akt/mTOR and AMPK pathways is central to cancer development, driving uncontrolled cell growth, metabolic disturbances, and resistance to cell death and therapy. Exercise has emerged as an effective non-drug strategy that can modify these pathways and influence tumor-related cellular processes. **Methods:** This review compiles evidence from 2015 to 2025 on how exercise impacts PI3K/Akt/mTOR and AMPK signaling in cancer. **Results:** Findings show that exercise activates AMPK, an energy sensor that boosts glucose uptake, insulin sensitivity, autophagy, and mitochondrial biogenesis. Through AMPK activation, exercise reduces anabolic signaling and excessive protein synthesis, which often promotes tumor growth, while supporting healthier metabolism. At the same time, exercise inhibits the PI3K/Akt/mTOR pathway, reducing cell proliferation, affecting growth factors like insulin and IGF-1, and restoring metabolic balance across tissues. These combined effects improve cellular stability, lessen tumor-promoting mechanisms, and may enhance responsiveness to cancer treatments, making exercise a valuable complement for cancer prevention and therapy. Most current insights come from preclinical studies or epidemiological data, with few clinical trials examining exercise-induced molecular changes in human tumors. **Conclusion:** More research is needed to identify optimal exercise regimens, understand pathway-specific effects, and evaluate their clinical relevance to better incorporate exercise into personalized cancer care.

Keywords: Exercise- PI3K/Akt/mTOR- AMPK- Cancer- Insulin sensitivity- Tumor Metabolism- Exercise Oncology

Asian Pac J Cancer Care, 11 (3), 467-476

Submission Date: 12/28/2025

Acceptance Date: 03/11/2026

Corresponding Authors:

Dr. Azim akbarzadehkhayavi and Mohsen Mir

Professor of Institute Pasteur of Iran in Department Nanobiotechnology, Tehran, Iran.

Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Email: azimakbarzadehkhayavi@gmail.com, mohsenniktel.67@gmail.com

Introduction

Despite progress in detection and treatment, cancer remains a significant public health issue worldwide. In the United States, cancer has consistently been the second leading cause of death since 1937 [1]. During 2020 and 2021, cancer deaths in the USA surpassed those from COVID-19, despite the ongoing pandemic, with about 600,000 cancer deaths in 2020 compared to approximately 350,000 from COVID-19 [2, 3]. Projections for 2024 estimate that the US will see 2 million new cancer cases and over 600,000 deaths [4, 5]. The PI3K/Akt/mTOR pathway is frequently overactive in many solid tumors, including breast and ovarian cancers. In normal cells, this pathway plays a crucial role in supporting growth, proliferation, and survival [6-10]. Research on molecular signaling has advanced our understanding of disease mechanisms and led to the discovery of biomarkers, drug targets, and innovative therapies [11].

As shown in Table 1, In tumor tissues, activation of the PI3K/Akt/mTOR and AMPK pathways can be evaluated using histopathological markers [12]. PI3K/Akt activation is often measured with phospho-Akt antibodies (Ser473/Thr308) and is linked to nuclear and cytoplasmic localization; it also correlates with proliferation markers like Ki-67. mTORC1 activity can be assessed through phospho-S6 and phospho-4E-BP1 staining, while mTORC2 affects cytoskeletal organization [13]. PTEN loss is a key upstream driver of PI3K signaling [14]. AMPK activity can be tracked using phospho-AMPK (Thr172), which may indicate tumor-suppressive or adaptive responses [15]. These findings highlight the heterogeneity of signaling within tumor regions and underscore the translational importance of preclinical research on exercise-induced modulation of these pathways.

Clinical tissue studies highlight the prevalence and prognostic relevance of key signaling biomarkers. Phospho-AKT is detectable in a substantial proportion of tumors (e.g., ~60 % of colorectal cancers) and is associated with advanced stage and poor outcomes. Elevated phospho-S6 correlates with metastasis and shorter survival in lung adenocarcinoma. Phospho-AMPK is present in colorectal and breast tumors, with higher levels sometimes

linked to better prognosis, though context-dependent. While these studies support the relevance of PI3K/AKT/mTOR and AMPK signaling in human cancers, links to exercise remain to be confirmed [16, 17].

The PI3K/AKT/mTOR pathway, a highly conserved intracellular pathway in eukaryotic cells, is crucial for cell metabolism and regulates processes such as growth, proliferation, survival, motility, adhesion, and differentiation [18]. Its frequent dysregulation in many diseases has made it a key focus for identifying biomarkers and potential therapeutic targets. The phosphoinositide 3-kinase (PI3K) can be activated by receptor tyrosine kinases (RTKs), including platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR), which promote cell proliferation and migration, as well as the insulin-like growth factor receptor (IGFR), which stimulates growth and survival, and the insulin receptor (IR), which helps maintain metabolic balance [19-21].

The PI3K/AKT/mTOR signaling pathway is a crucial regulator of essential cellular processes such as proliferation, metabolism, survival, and immune response. In cancer, improper regulation promotes malignant transformation, tumor growth, resistance to therapy, and immune evasion. Although many studies have been conducted, a comprehensive understanding of this pathway's complex role in tumor biology and therapy is still lacking [22]. Exercise has been shown to modulate AMPK and mTOR pathways, restoring signaling balance and improving metabolic regulation.

This review combines insights from aging biology, exercise physiology, and molecular metabolism to underscore the therapeutic potential of targeting AMPK/mTOR signaling through physical activity to address insulin resistance in older adults [23]. While previous research has largely focused on the effects of exercise in aging skeletal muscle, studies also suggest potential relevance in cancer biology. This article examines the impact of exercise on these pathways in cancer research.

2. Exercise-Induced Molecular Mechanisms

2.1. Adiponectin-mediated AMPK Activation

Exercise and weight loss elevate circulating

Table 1. Most Exercise-related Evidence Comes from Systemic Compartments (muscle, liver, adipose tissue) Rather than Tumor Tissue. Direct human tumor data remain limited.

Pathway Node	Tissue Marker (IHC)	Typical Findings in Cancer	Preclinical / Hypothetical Exercise Response
PI3K/Akt	Phospho-Akt (Ser473/Thr308)	Nuclear/cytoplasmic; correlates with proliferation indices (Ki-67)	Exercise may reduce Akt activation via systemic insulin/IGF-1 reduction; limited direct tumor evidence
mTORC1	Phospho-S6, Phospho-4E-BP1	Elevated in many solid tumors; promotes translation and growth	Exercise inhibits mTORC1 via AMPK activation, suppressing anabolic signaling
mTORC2	Rictor	Regulates cytoskeletal organization; heterogeneous	Modulated indirectly via Akt regulation and systemic effects of exercise
AMPK	Phospho-AMPK (Thr172)	Variable; context-dependent (tumor-suppressive vs stress-adaptive)	Activated by exercise, adiponectin, and myokines; promotes energy balance, autophagy, and anti-inflammatory signaling
PTEN	PTEN loss (IHC/genetic)	Constitutive PI3K/Akt activation	PTEN-deficient tumors may rely more on AMPK-mediated mTOR inhibition than insulin/IGF-1 reduction

adiponectin, which binds to AdipoR1/R2 receptors, activating upstream kinases such as LKB1 and CaMKK β to stimulate AMPK. This pathway enhances fatty acid oxidation, insulin sensitivity, and suppresses anabolic processes that support tumor growth [24, 25]. Exercise and weight loss elevate circulating adiponectin, which activates AMPK via AdipoR1/R2 signaling in multiple tissues. This adipokine-mediated mechanism may contribute to AMPK-dependent effects on tumor metabolism and systemic energy balance.

2.2. Myokines and Cytokine Remodeling

Acute bouts of exercise induce IL-6 release from skeletal muscle, functioning as an anti-inflammatory myokine that activates AMPK and increases glucose uptake. Chronic exercise reduces TNF- α and IL-1 β from adipose and myeloid cells, decreasing NF- κ B activation and subsequent PI3K/Akt signaling [26]. Regular exercise shifts the systemic cytokine milieu from a pro-inflammatory (TNF- α , IL-1 β dominant) to an anti-inflammatory state, reducing NF- κ B activation in both tumor and stromal cells. This cytokine remodeling complements dire.

2.3. IRS-1/IRS-2 Feedback Loop

mTORC1 phosphorylates and destabilizes IRS-1/IRS-2 under nutrient-rich conditions. Exercise-induced AMPK activation inhibits mTORC1, stabilizing IRS-1/2 and potentially increasing PI3K/Akt signaling via feedback loops [27].

2.4. PTEN-Loss Tumors

Tumors with PTEN loss exhibit constitutive PI3K/Akt activation independent of insulin/IGF-1. Exercise benefits in such tumors may rely primarily on AMPK-mediated mTOR inhibition and metabolic reprogramming rather than systemic insulin/IGF-1 reduction [28].

Importantly, mTORC1 normally phosphorylates and destabilizes insulin receptor substrates (IRS-1/IRS-2). When mTORC1 is inhibited either by AMPK activation or pharmacologically IRS-1/2 levels recover, leading to increased PI3K/Akt signaling via a compensatory feedback loop. Exercise-induced AMPK activation may activate both branches (AMPK \rightarrow mTORC1 inhibition AND enhanced insulin sensitivity), but this dual regulation warrants further investigation in tumor contexts.

EDIT: Contextualized PTEN-loss impact

2.5. HIF-1 α and Tumor Perfusion

Exercise improves tumor perfusion and oxygenation, reducing hypoxia-induced HIF-1 α stabilization and downstream pro-growth and metabolic adaptations [29]. Exercise-induced improvements in cardiovascular function enhance tumor perfusion and oxygenation, reducing HIF-1 α stabilization and attenuating HIF-1 α -dependent angiogenic and metabolic adaptations in tumor cells.

EDIT: Added tumor vascular/HIF-1 α mechanism

2.6. Autophagy Duality

AMPK-driven autophagy is tumor-suppressive

in pre-malignant and early tumors but may support survival in metabolically stressed established tumors. Exercise-induced AMPK activation thus has context-dependent effects on autophagy [25].

While AMPK-driven autophagy is generally tumor-suppressive in pre-malignant and early tumor contexts, in metabolically stressed established tumors, autophagy may conversely support cancer cell survival and drug resistance. The net effect of exercise-induced AMPK activation on autophagy in cancer is therefore context-dependent

EDIT: Clarified dual role of autophagy

Materials and Methods

Search Strategy

For this review, we conducted a comprehensive search of PubMed, Google Scholar, and Scopus databases covering 2015–2025. The keywords used were neoplasm, cancer, signaling, exercise, and PI3K/AKT/mTOR. Eligible studies included original, peer-reviewed research articles written in English that investigated the molecular or physiological effects of exercise on cancer progression through modulation of these signaling pathways. Exclusion criteria encompassed review articles, meta-analyses, book chapters, editorials, letters to the editor, conference abstracts, non-English publications, and studies not directly related to the research question.

The selection process was conducted in two stages: first, screening titles and abstracts for relevance, and then reviewing the full texts of potentially eligible articles. The Zotero reference management software was used to organize, categorize, and remove duplicate entries, ensuring a systematic and transparent selection of studies.

Results and Discussion

The role of PI3K/Akt/mTOR pathway in the incidence of cancer

Previous studies highlighted the significance of the mTOR pathway in cancer development. PIK3CA is overexpressed in ovarian [30] and cervical cancers [31], with mutations also noted in breast cancer, glioblastoma, and gastric cancer [32]. Overexpression of Akt1 has been identified in gastric carcinoma, while Akt2 overexpression occurs in ovarian and pancreatic cancers [33]. Although Akt mutations are rare, Carpten et al. [34] reported somatic mutations in Akt1 in a small percentage of human breast, ovarian, and colorectal cancers. Additionally, mTOR complex 1 (mTORC1) may promote mRNA translation, protein synthesis, and cellular proliferation [35]. Activation of a second mTOR complex (mTORC2), which regulates the cytoskeleton, likely results from Akt loop feedback [36]. Balsara et al. [37] observed that 74% of non-small cell lung cancer (NSCLC) patient specimens showed positive mTOR staining using tissue microarray (TMA). Rictor, a subunit of mTORC2, enhances mTORC2 assembly and activity, increasing the proliferation and invasion capabilities of glioma cells. Preclinical data indicate that exercise-activated AMPK and mTORC1

suppression may reduce proliferative and anabolic activity in tumor cells, providing a potential complementary approach for cancer prevention or treatment. However, clinical evidence in human tumors remains limited, and more research is necessary [38]. Overall, these findings show that abnormal activation of the PI3K/Akt/mTOR pathway is crucial in tumor formation.

The PI3K-AKT-mTOR signaling pathway is vital for cancer cell growth and survival. Lipid kinases called PI3K are key regulators in many essential cellular processes, such as cell survival, growth, and differentiation [39, 40]. This pathway features several crucial nodes that lead to a variety of functional outcomes. Activation of downstream targets, such as the mammalian target of rapamycin (mTOR), by AKT promotes cell proliferation and controls translation in response to growth factors, primarily through phosphorylation of the protein synthesis machinery [41]. mTOR promotes translation by phosphorylating ribosomal protein S6 kinases (S6K) and 4E-binding protein 1 (4E-BP1). When 4e-BP1 is phosphorylated, it releases eukaryotic translation initiation factor 4E (eIF4E), which has anti-apoptotic effects in vitro [42, 43]. The TSC1-TSC2 complex negatively regulates this process. The TSC1/TSC2 complex inhibits the small GTPase Rheb, thereby suppressing mTORC1 activity and keeping 4E-BP1 in a hypophosphorylated state, in which it binds eIF4E and represses cap-dependent translation. [44, 45]. Additionally, AKT phosphorylates and inhibits TSC2, further complicating this pathway. Interestingly, while rapamycin and its analogues can inhibit mTOR, this may activate upstream proteins such as AKT via a feedback loop disruption [46, 47]. The PI3K/Akt/mTOR pathway regulates key normal cellular processes such as proliferation, growth, survival, and mobility, all of which are also crucial for tumour development. Abnormalities in this pathway are common in y types of tumors, which makes its components attractive targets for cancer therapy. [10, 14, 20, 48, 49].

In addition to supporting proliferation and survival, this pathway also plays a role in signalling metabolic and angiogenic processes. Additionally, the PI3K-AKT pathway interacts with complex molecular mechanisms that regulate cellular energy and glucose metabolism.

AKT phosphorylates and inhibits targets such as glycogen synthase kinase-3 (GSK3), phosphodiesterase-3 B, protein phosphatase 2A, and Raf-1. The PI3K signaling pathway also plays a role in controlling growth, proliferation, senescence, and angiogenesis, which are regulated by vascular endothelial growth factor (VEGF) transcriptional activation and hypoxia-inducible factor-1 alpha (HIF-1 α) expression [50, 51]. This brief overview emphasises the pathway's involvement in critical cell growth processes, underscoring its complexity and importance at multiple nodes [52]. Given the diversity of signaling dependencies across cancer types, the strength of epidemiologic evidence and mechanistic plausibility for exercise varies substantially. Exercise elicits cancer-type-specific effects on PI3K/Akt/mTOR and AMPK pathways. It may modulate hormone-sensitive tumors via the IGF-1/insulin axis, alter responses to targeted therapies such as PI3K/mTOR inhibitors, and influence immune checkpoint inhibitor efficacy. Stage-specific evidence is strongest for primary prevention, moderate for adjuvant/survivorship settings (particularly breast and colon cancer), and limited in metastatic disease, where the focus is primarily on functional and quality-of-life benefits. General exercise guidance includes ≥ 150 minutes/week of moderate aerobic activity plus two resistance training sessions per week [53]. For a consolidated cancer-type-specific summary of mechanistic and epidemiologic evidence, see Table 2.

PI3K/AKT/mTOR signaling and exercise

Cancer cells primarily exhibit increased proliferation, decreased apoptosis, and enhanced survival, driven by the regulation of critical signaling molecules and pathways [54, 55]. The activation of phosphatidylinositol 3-kinase (PI3K)-Akt and Ras-ERK (Erk1/2) pathways occurs when growth factors bind to cell surface receptors, promoting cell growth and longevity [56, 57]. Akt activation leads to downstream effectors, including mTOR and S6 kinase, which stimulate protein synthesis and cell growth [58, 59]. Moreover, Akt phosphorylates Bad, inhibiting apoptosis and enhancing cell survival [60].

Akt, a proto-oncogene, is frequently overexpressed in many cancers, including NSCLC, contributing to

Table 2. Summary of Exercise-Related Evidence Across Cancer Types: Epidemiologic Support, Mechanistic Plausibility (PI3K/Akt/mTOR, AMPK), and Clinical Utility

Cancer Type	Epidemiologic Evidence	Mechanistic Plausibility	Clinical Application
Breast	Strong	AMPK activation, IGF-1/insulin modulation, myokines	Prevention, adjuvant support, survivorship
Colon	Strong	AMPK, mTOR inhibition, cytokine shifts	Prevention, adjuvant support
Lung	Moderate	AMPK, HIF-1 α reduction	Prevention, QOL in palliative care
Prostate	Moderate	AMPK, IGF-1 axis	Prevention, survivorship
Ovarian	Limited	AMPK, mTOR	Prevention only
Pancreatic	Limited	AMPK, metabolic reprogramming	Prevention, palliative focus
Glioblastoma	Limited	HIF-1 α , perfusion	Palliative support
Melanoma	Limited	AMPK, immune modulation	Prevention
HCC	Moderate	AMPK, mTOR, cytokines	Prevention, survivorship

resistance to chemotherapy and radiation therapy [37, 57]. Ras signaling is also often activated in cancers like NSCLC, leading to Erk1/2 activation, increased proliferation, and therapy resistance [49-51]. This activation downstream of Erk1/2 promotes cell proliferation and contributes to chemo- and radiation resistance [61]. Thus, targeting or inhibiting the Akt and Ras-Erk1/2 pathways could be an effective strategy for preventing and treating lung cancer. Therefore, targeting the Akt and Ras-ERK pathways may be a promising therapeutic approach for cancers such as NSCLC.

Regular exercise is associated with reduced cancer risk [53], including prostate [53] and breast cancer [62]. Breast cancer patients engaged in light aerobic exercise showed higher survival rates than sedentary patients [63]. Additionally, increasing physical activity to more than 1.8 Mets/day (such as running) was associated with nearly a 90% reduction in cancer mortality risk [64].

While the link between exercise and lung cancer has not been thoroughly studied, evidence suggests that engaging in regular exercise more than 4 hours weekly at a moderate intensity (>4.5 MET) can lower the risk of NSCLC adenocarcinomas in both men and women compared to those exercising less than 4 hours weekly at a low intensity (<4.5 MET) [65, 66]. Additionally, regular exercisers seem to have a 20–40% lower risk of lung cancer relative to sedentary individuals. Nonetheless, despite this epidemiological data, the specific factors and mechanisms through which exercise exerts its anticancer effects remain unclear [67].

Mechanistically, exercise can modulate key signaling pathways involved in tumor growth. Weight loss and exercise reduce IGF-1, insulin, and leptin levels, thereby diminishing activation of Ras-MAPK and PKB/Akt-PI3K pathways, which normally promote proliferation and inhibit apoptosis [68-70]. Furthermore, exercise inhibits mTOR activity in tissues such as liver, brain, fat, and skeletal muscle, contributing to reduced tumor-promoting signaling [68, 71, 72].

The AMPK pathway and its role in cancer inhibition

AMP-activated protein kinase (AMPK) is a highly conserved enzyme made up of a catalytic α subunit and two regulatory subunits, β and γ . This pathway has become a crucial regulator of cellular energy balance and plays a role in cancer suppression. It is found in various tissues, including liver and skeletal muscle [73, 74]. The α -subunit contains a crucial threonine residue (Thr172), where phosphorylation by upstream kinases activates AMPK. These kinases include liver kinase B1 (LKB1), calcium/calmodulin-dependent protein kinase (CaMKK) [75], and transforming growth factor β (TGF- β)-activated kinase (TAK1) [75]. Mutations in these upstream kinases may cause AMPK dysregulation and elevate cancer risk, for example. Individuals with Peutz-Jeghers syndrome who have germline mutations in LKB1 show a higher cancer risk [75]. AMPK can also be triggered by external changes such as ATP depletion, low glucose, or alterations in NADPH levels [76]. Beyond physiological stressors, both pharmacological and natural compounds

can activate AMPK, suggesting possible therapeutic strategies. Certain drugs and natural compounds can activate AMPK, including metformin and some NSAIDs [77, 78], polyphenols like resveratrol [79-81], flavonoids such as quercetin [82], and herbal compounds like berberine [83-85]. Activation of AMPK by NSAIDs and anti-inflammatory drugs suggests a role for AMPK in inflammation. Once active, AMPK influences multiple effector proteins involved in regulatory pathways that may lead to cancer development. Regarding cancer metabolism, the mammalian target of Rapamycin (mTOR) is a key target of AMPK, with ongoing efforts to develop clinical interventions [86]. AMPK also regulates p53 [87] and modulates transcription factors and co-regulators that control the cell cycle [88-90]. Through AMPK regulates key targets like mTOR and p53, broadly influencing cell cycle, apoptosis, and tumor metabolism. AMPK frequently exerts tumor-suppressing effects by inhibiting mTORC1 and restricting anabolic metabolism; however, its role depends on the context. In established tumors experiencing metabolic or hypoxic stress, AMPK activation might also support cell survival through promoting autophagy and metabolic processes adaptation [91].

AMPK has been shown to have tumor-suppressing functions in multiple experimental cancer models; however, evidence at the tissue level in human tumors suggests that its role might be dependent on the context and can differ based on tumor stage and microenvironmental conditions. Together, these mechanisms produce tumor-suppressing effects in various cancer types, as shown by research in NSCLC, CRC, HCC, melanoma, and breast cancer. In NSCLC, its activation correlates with better prognosis and decreased cell proliferation. In CRC, AMPK significantly influences cancer cell survival and promotes apoptosis. In HCC, activating AMPK is linked to hindering tumor growth and enhancing prognosis. In melanoma, AMPK triggers cancer cell death and diminishes tumor expansion. In breast cancer, it suppresses cell growth and supports survival under stressful conditions. While AMPK activation can limit anabolic signaling and support anti-proliferative responses, studies of human tumor tissues suggest that AMPK may also support metabolic adaptation and cell survival under tumor-associated stress conditions [73]. AMPK frequently exerts tumor-suppressing effects by inhibiting mTORC1 and restricting anabolic metabolism; however, its role depends on the context. In established tumors experiencing metabolic or hypoxic stress, AMPK activation might also support cell survival through promoting autophagy and metabolic processes adaptation.

The relationship between AMPK and exercise

AMPK (AMP-activated protein kinase) is an evolutionarily conserved enzyme that senses cellular energy levels and is found in all mammalian cells. It is essential in maintaining cellular energy balance, and its activity can be influenced by physiological triggers such as exercise. In humans, exercise activates AMPK in skeletal muscles, and in rodents, it also activates in adipose tissue, liver, and possibly other organs due to increased AMP/

ATP ratios. This tissue-specific activation is fundamental to many of the systemic metabolic changes seen during exercise. When active, like glucose uptake and fatty acid oxidation, while it suppresses energy-consuming processes such as protein and lipid synthesis. Since exercise strongly stimulates AMPK activity, it serves as a natural model for studying these energy regulation mechanisms pathways. Exercise is arguably the most significant natural activator of AMPK and serves as an ideal model for exploring its various physiological roles. Moreover, it enhances metabolic health in rodents displaying metabolic syndrome traits, similar to the effects of AMPK-activating drugs [92-96]. This suggests that the health benefits of regular physical activity may partly stem from AMPK activation [97]. Animal studies show that both acute exercise and regular training boost cardiac AMPK phosphorylation and activity. Overall, these findings imply that activating AMPK alone can promote glucose and fatty acid metabolism [93]. Ultimately, these results suggest that activation of AMPK through exercise plays a crucial role in improving energy metabolism and could be a factor in the overall health advantages of physical activity.

Exercise affects crosstalk between PI3K/Akt/mTOR and AMPK

Dysregulation of nutrient-sensitive pathways like AMP-activated protein kinase (AMPK) and mechanistic target of rapamycin (mTOR) is key to metabolic imbalance and abnormal cell growth seen in aging and cancer [23]. These pathways work together to regulate energy use, protein production, and glucose metabolism, which also influence cell growth and survival [98]. Exercise influences these kinases, helping improve metabolic signaling. By activating AMPK and regulating mTOR activity, exercise boosts mitochondrial biogenesis, increases glucose uptake, and supports healthy growth processes, thereby preventing out-of-control signaling [99]. In cancer, the interaction between AMPK and mTOR offers therapeutic potential, as activating AMPK can inhibit tumor-promoting mTOR activity, reduce abnormal protein production, and promote autophagy of damaged cell parts. Therefore, targeting how exercise affects the PI3K/Akt/mTOR and AMPK pathways could be an effective approach to managing cellular metabolism and controlling growth in cancer prevention and treatment [23]. Importantly, the metabolic effects of exercise-induced AMPK activation also contribute to cancer protection by connecting energy regulation with tumor suppression.

Exercise and physical activity can activate AMPK, a tumor suppressor protein linked to numerous cancers [70]. Once activated through exercise, AMPK inhibits cancer cell growth by regulating cellular metabolism, blocking pathways that support cell division, and decreasing insulin resistance and IGF-1 levels [100-102]. Therefore, engaging in exercise not only boosts metabolic health but also acts as a natural method to help prevent cancer and support treatment.

In conclusion, exercise represents a promising, multidimensional intervention in cancer prevention and

management. By activating AMPK and simultaneously inhibiting mTOR signaling, exercise restores metabolic balance, improves insulin sensitivity, promotes autophagy, and reduces proliferative signaling in tumor and systemic tissues. Systemic mediators, including adiponectin and myokines, and anti-inflammatory cytokine shifts contribute to these effects. The impact of exercise is influenced by tumor-specific factors such as PTEN status, hypoxia, and stage, underscoring the importance of context in interpreting its anticancer potential. While evidence supports strong benefits in early-stage and prevention settings, clinical trials in human tumors are needed to clarify optimal exercise regimens, dose, and interactions with conventional therapies. In conclusion, regular physical activity should be considered a complementary strategy in oncology, offering metabolic, molecular, and systemic benefits that may enhance the efficacy of standard treatments and contribute to improved patient outcomes.

Ethics approval

This manuscript does not encompass any research involving animals or people.

Conflict and interest

The authors assert no conflict of interest in this work.

Acknowledgments

Not Applicable

References

- Harding MC, Sloan CD, Merrill RM, Harding TM, Thacker BJ, Thacker EL. Transitions From Heart Disease to Cancer as the Leading Cause of Death in US States, 1999–2016. *Preventing Chronic Disease*. 2018 Dec 13;15:E158. <https://doi.org/10.5888/pcd15.180151>
- Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. *JAMA*. 2021 05 11;325(18). <https://doi.org/10.1001/jama.2021.5469>
- Shiels MS, Haque AT, Berrington de González A, Freedman ND. Leading Causes of Death in the US During the COVID-19 Pandemic, March 2020 to October 2021. *JAMA internal medicine*. 2022 08 01;182(8). <https://doi.org/10.1001/jamainternmed.2022.2476>
- Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA: a cancer journal for clinicians*. 2024 02;74(1). <https://doi.org/10.3322/caac.21820>
- Tan T, Shi P, Abbas MN, Wang Y, Xu J, Chen Y, Cui H. Epigenetic modification regulates tumor progression and metastasis through EMT (Review). *International journal of oncology*. 2022 06;60(6). <https://doi.org/10.3892/ijo.2022.5360>
- Pourbarkhordar V, Rahmani S, Roohbakhsh A, Hayes AW, Karimi G. Melatonin effect on breast and ovarian cancers by targeting the PI3K/Akt/mTOR pathway. *IUBMB life*. 2024 Dec;76(12). <https://doi.org/10.1002/iub.2900>
- Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. *Seminars in cancer biology*. 2022 Oct;85. <https://doi.org/10.1016/j.semcancer.2021.06.019>
- Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in

- Breast Cancer: From Molecular Landscape to Clinical Aspects. *International journal of molecular sciences*. 2020 Dec 26;22(1). <https://doi.org/10.3390/ijms22010173>
9. Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. *Seminars in cancer biology*. 2019 Dec;59. <https://doi.org/10.1016/j.semcancer.2019.05.012>
 10. Ersahin T, Tuncbag N, Cetin-Atalay R. The PI3K/AKT/mTOR interactive pathway. *Molecular bioSystems*. 2015 07;11(7). <https://doi.org/10.1039/c5mb00101c>
 11. Omolekan TO, Chamcheu JC, Buerger C, Huang S. PI3K/AKT/mTOR Signaling Network in Human Health and Diseases. *Cells*. 2024 09 06;13(17). <https://doi.org/10.3390/cells13171500>
 12. Dardor R, Moniem S, Elbaiomy M, Megahed N, Shabana H. Expression of PI3K-AKT-mTOR signaling pathway in gastric cancer. *Gastroenterology hepatology*. 2023;14:71-7.
 13. Del Pino-Molina L, Torres Canizales JM, Rodríguez-Pena R, López-Granados E. Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. *Cytometry. Part B, Clinical cytometry*. 2021 07;100(4). <https://doi.org/10.1002/cyto.b.21956>
 14. Glaviano A, Foo A, Lam HY, Yap KCH, Jacot W, Jones RH, Eng H, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. *Molecular cancer*. 2023 08 18;22(1). <https://doi.org/10.1186/s12943-023-01827-6>
 15. Keerthana CK, Rayginia TP, Shifana SC, Anto NP, Kalimuthu K, Isakov N, et al. The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. *Frontiers in immunology*. 2023 02 15;14. <https://doi.org/10.3389/fimmu.2023.1114582>
 16. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, et al. Histological evaluation of AMPK signalling in primary breast cancer. *BMC cancer*. 2009 09 01;9. <https://doi.org/10.1186/1471-2407-9-307>
 17. Ma Y, Chen M, Xu Z. Clinicopathological significance of AKT and phosphorylated AKT expression in hepatocellular carcinoma: A Meta-Analysis. *BMC cancer*. 2025 Oct 31;25(1). <https://doi.org/10.1186/s12885-025-14948-6>
 18. Ghodsinia AA, Lego J-AMT, Garcia RL. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants. *Cells*. 2020 04 30;9(5). <https://doi.org/10.3390/cells9051116>
 19. Meco M, Giustiniano E, Nisi F, Zulli P, Agosteo E. MAPK, PI3K/Akt Pathways, and GSK-3 β Activity in Severe Acute Heart Failure in Intensive Care Patients: An Updated Review. *Journal of cardiovascular development and disease*. 2025 07 10;12(7). <https://doi.org/10.3390/jcdd12070266>
 20. Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K Pathway in Human Disease. *Cell*. 2017 08 10;170(4). <https://doi.org/10.1016/j.cell.2017.07.029>
 21. Quan C, Xiao J, Liu L, Duan Q, Yuan P, Zhu F. Protein Kinases as Tumor Biomarkers and Therapeutic Targets. *Current pharmaceutical design*. 2017 Nov 16;23(29). <https://doi.org/10.2174/1381612823666170720113216>
 22. Jiang M, Zhang K, Zhang Z, Zeng X, Huang Z, Qin P, et al. PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment. *MedComm*. 2025 07 30;6(8). <https://doi.org/10.1002/mco2.70295>
 23. Mingzheng X, You W. AMPK/mTOR balance during exercise: implications for insulin resistance in aging muscle. *Molecular and cellular biochemistry*. 2025 Dec;480(12). <https://doi.org/10.1007/s11010-025-05362-4>
 24. Tuğral A, Arıbaş Z, Kaya Uçar G, Arslan FD, Bakar Y, Karakoyun I, et al. The effect of supervised aerobic exercise on adipokine and myokine biomarkers in patients with cancer during systemic chemotherapy: a single-blinded prospective controlled trial. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer*. 2025 08 02;33(8). <https://doi.org/10.1007/s00520-025-09788-w>
 25. García-Miranda A, Garcia-Hernandez A, Castañeda-Saucedo E, Navarro-Tito N, Maycotte P. Adipokines as Regulators of Autophagy in Obesity-Linked Cancer. *Cells*. 2022 Oct 14;11(20). <https://doi.org/10.3390/cells11203230>
 26. Wang J, He Y, Wang Z, Wang Z, Miao Y, Choi JY. Effects of different exercise prescription parameters on metabolic and inflammatory biomarkers in cancer patients: a systematic review, meta-analysis, and meta-regression. *Frontiers in immunology*. 2025 08 14;16. <https://doi.org/10.3389/fimmu.2025.1663560>
 27. Alasadi A, Fadhil N, Chen S. Deciphering the critical roles of the AMPK/mTOR signaling pathway in cancer cell metabolism. *World Academy of Sciences Journal*. 2025;7(6):103..
 28. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. *Apoptosis : an international journal on programmed cell death*. 2004 Nov;9(6). <https://doi.org/10.1023/B:APPT.0000045801.15585.dd>
 29. Buzaglo GBB, Telles GD, Araújo RB, Junior GDS, Ruberti OM, Ferreira MLV, et al. The Therapeutic Potential of Physical Exercise in Cancer: The Role of Chemokines. *International journal of molecular sciences*. 2024 Dec 23;25(24). <https://doi.org/10.3390/ijms252413740>
 30. Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. *American journal of cancer research*. 2015 04 15;5(5).
 31. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. *Nature genetics*. 1999 01;21(1):99-102. <https://doi.org/10.1038/5042>
 32. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science (New York, N.Y.)*. 2004 04 23;304(5670). <https://doi.org/10.1126/science.1096502>
 33. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proceedings of the National Academy of Sciences of the United States of America*. 1996 04 16;93(8). <https://doi.org/10.1073/pnas.93.8.3636>
 34. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. *Molecular carcinogenesis*. 1998 02;21(2).
 35. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. *Nature*. 2007 07 26;448(7152). <https://doi.org/10.1038/nature05933>
 36. Tasian SK, Teachey DT, Rheingold SR. Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies. *Frontiers in oncology*. 2014 05 16;4. <https://doi.org/10.3389/fonc.2014.00108>
 37. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. *Carcinogenesis*. 2004 Nov;25(11). <https://doi.org/10.1093/carcin/bgh226>

38. Fan QW, Weiss WA. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors. *Methods in molecular biology* (Clifton, N.J.). 2012;821. https://doi.org/10.1007/978-1-61779-430-8_22
39. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. *Nature reviews. Cancer*. 2009 08;9(8). <https://doi.org/10.1038/nrc2664>
40. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. *Nature reviews. Cancer*. 2002 07;2(7). <https://doi.org/10.1038/nrc839>
41. Wendel H-G, Stanchina Ed, Fridman JS, Malina A, Ray S, Kogan S, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. *Nature*. 2004 03 18;428(6980). <https://doi.org/10.1038/nature02369>
42. Schmelzle T, Hall MN. TOR, a central controller of cell growth. *Cell*. 2000 Oct 13;103(2). [https://doi.org/10.1016/S0092-8674\(00\)00117-3](https://doi.org/10.1016/S0092-8674(00)00117-3)
43. Lazaris-Karatzas A, Montine KS, Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. *Nature*. 1990 06 07;345(6275). <https://doi.org/10.1038/345544a0>
44. Dan HC, Sun M, Yang L, Feldman RI, Sui X-M, Ou CC, et al. Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. *The Journal of biological chemistry*. 2002 09 20;277(38). <https://doi.org/10.1074/jbc.M205838200>
45. Hengstschläger M, Rosner M, Fountoulakis M, Lubec G. Tuberous sclerosis genes regulate cellular 14-3-3 protein levels. *Biochemical and biophysical research communications*. 2003 Dec 19;312(3). <https://doi.org/10.1016/j.bbrc.2003.10.170>
46. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. *The Journal of cell biology*. 2004 07 19;166(2). <https://doi.org/10.1083/jcb.200403069>
47. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, Bajraszewski N, et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. *The Journal of clinical investigation*. 2003 Oct;112(8). <https://doi.org/10.1172/JCI17222>
48. Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, et al. The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review. *Cancers*. 2021 08 05;13(16). <https://doi.org/10.3390/cancers13163949>
49. Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. *International journal of molecular sciences*. 2013 04 15;14(4). <https://doi.org/10.3390/ijms14048213>
50. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. *Genes & development*. 1998 Nov 15;12(22). <https://doi.org/10.1101/gad.12.22.3499>
51. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang B-H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. *The Journal of biological chemistry*. 2004 Oct 29;279(44). <https://doi.org/10.1074/jbc.M404097200>
52. Khan K, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. *Chinese journal of cancer*. 2013 05;32(5). <https://doi.org/10.5732/cjc.013.10057>
53. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. *JAMA internal medicine*. 2016 06 01;176(6). <https://doi.org/10.1001/jamainternmed.2016.1548>
54. Portt L, Norman G, Clapp C, Greenwood M, Greenwood MT. Anti-apoptosis and cell survival: a review. *Biochimica et biophysica acta*. 2011 01;1813(1). <https://doi.org/10.1016/j.bbamcr.2010.10.010>
55. Ilagan E, Manning BD. Emerging role of mTOR in the response to cancer therapeutics. *Trends in cancer*. 2016 05;2(5). <https://doi.org/10.1016/j.trecan.2016.03.008>
56. Naidoo J, Drilon A. KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. *Advances in experimental medicine and biology*. 2016;893. https://doi.org/10.1007/978-3-319-24223-1_8
57. Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. *Lung cancer management*. 2014 01 01;3(1). <https://doi.org/10.2217/lmt.13.72>
58. Xie Y, Naizabekov S, Chen Z, Tokay T. Power of PTEN/AKT: Molecular switch between tumor suppressors and oncogenes. *Oncology letters*. 2016 07;12(1). <https://doi.org/10.3892/ol.2016.4636>
59. Vicary GW, Roman J. Targeting the Mammalian Target of Rapamycin in Lung Cancer. *The American journal of the medical sciences*. 2016 Nov;352(5). <https://doi.org/10.1016/j.amjms.2016.08.014>
60. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. *Journal of cellular and molecular medicine*. 2005 03;9(1). <https://doi.org/10.1111/j.1582-4934.2005.tb00337.x>
61. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. *Journal of cellular physiology*. 2011 Nov;226(11). <https://doi.org/10.1002/jcp.22647> PMID 21302297
62. Fournier A, Dos Santos G, Guillas G, Bertsch J, Duclos M, Boutron-Ruault M-C, et al. Recent recreational physical activity and breast cancer risk in postmenopausal women in the E3N cohort. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. 2014 09;23(9). <https://doi.org/10.1158/1055-9965.EPI-14-0150>
63. Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. *JAMA*. 2005 05 25;293(20). <https://doi.org/10.1001/jama.293.20.2479>
64. Williams PT. Significantly greater reduction in breast cancer mortality from post-diagnosis running than walking. *International journal of cancer*. 2014 09 01;135(5). <https://doi.org/10.1002/ijc.28740>
65. Thune I, Lund E. The influence of physical activity on lung-cancer risk: A prospective study of 81,516 men and women. *International journal of cancer*. 1997 01 06;70(1). [https://doi.org/10.1002/\(sici\)1097-0215\(19970106\)70:1<57::aid-ijc9>3.0.co;2-5](https://doi.org/10.1002/(sici)1097-0215(19970106)70:1<57::aid-ijc9>3.0.co;2-5)
66. Thune I, Furberg AS. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. *Medicine and science in sports and exercise*. 2001 06;33(6 Suppl). <https://doi.org/10.1097/00005768-200106001-00025>
67. Kruk J, Czerniak U. Physical activity and its relation to cancer risk: updating the evidence. *Asian Pacific journal of cancer prevention : APJCP*. 2013;14(7). <https://doi.org/10.7314/apjcp.2013.14.7.3993>
68. Wang Q, Zhou W. Roles and molecular mechanisms of physical exercise in cancer prevention and treatment. *Journal of sport and health science*. 2021 03;10(2). <https://doi.org/10.1007/s40201-021-00001-0>

- doi.org/10.1016/j.jshs.2020.07.008
69. Xie L, Wang W. Weight control and cancer preventive mechanisms: role of insulin growth factor-1-mediated signaling pathways. *Experimental biology and medicine* (Maywood, N.J.). 2013 02;238(2). <https://doi.org/10.1177/1535370213477602>
 70. Feng Y, Feng X, Wan R, Luo Z, Qu L, Wang Q. Impact of exercise on cancer: mechanistic perspectives and new insights. *Frontiers in immunology*. 2024 09 13;15. <https://doi.org/10.3389/fimmu.2024.1474770>
 71. Ballarò R, Beltrà M, De Lucia S, Pin F, Ranjbar K, Hulmi JJ, et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. 2019 04;33(4). <https://doi.org/10.1096/fj.201801862R>
 72. Watson K, Baar K, editors. mTOR and the health benefits of exercise. *Seminars in cell & developmental biology*. 2014 Dec;36. <https://doi.org/10.1016/j.semcdb.2014.08.013>
 73. Li W, Saud SM, Young MR, Chen G, Hua B. Targeting AMPK for cancer prevention and treatment. *Oncotarget*. 2015 04 10;6(10). <https://doi.org/10.18632/oncotarget.3629>
 74. Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. *Nature reviews. Molecular cell biology*. 2007 Oct;8(10). <https://doi.org/10.1038/nrm2249>
 75. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. *Proceedings of the National Academy of Sciences of the United States of America*. 2004 03 09;101(10). <https://doi.org/10.1073/pnas.0308061100>
 76. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. *Nature*. 2012 05 09;485(7400). <https://doi.org/10.1038/nature11066>
 77. Yao F, Ji GY, Zhang L. AMPK: a novel target controlling inflammation. *Sheng li xue bao : [Acta physiologica Sinica]*. 2012 06 25;64(3).
 78. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. *Cancer prevention research (Philadelphia, Pa.)*. 2014 04;7(4). <https://doi.org/10.1158/1940-6207.CAPR-13-0337>
 79. HWANG JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ. Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. *Annals of the New York Academy of Sciences*. 2007 01;1095. <https://doi.org/10.1196/annals.1397.047>
 80. Lin JN, Lin VCH, Rau KM, Shieh PC, Kuo DH, Shieh JC, et al. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. *Journal of agricultural and food chemistry*. 2010 02 10;58(3). <https://doi.org/10.1021/jf9035782>
 81. Rashid A, Liu C, Sanli T, Tsiani E, Singh G, Bristow RG, et al. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. *Radiation oncology (London, England)*. 2011 Oct 26;6. <https://doi.org/10.1186/1748-717X-6-144>
 82. Shen Y, Croft KD, Hodgson JM, Kyle R, Lee I-LE, Wang Y, et al. Quercetin and its metabolites improve vessel function by inducing eNOS activity via phosphorylation of AMPK. *Biochemical pharmacology*. 2012 Oct 15;84(8). <https://doi.org/10.1016/j.bcp.2012.07.016>
 83. Kim HS, Kim MJ, Kim EJ, Yang Y, Lee MS, Lim JS. Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. *Biochemical pharmacology*. 2012 02 01;83(3). <https://doi.org/10.1016/j.bcp.2011.11.008>
 84. Li Y, Wang P, Zhuang Y, Lin H, Li Y, Liu L, et al. Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes. *FEBS letters*. 2011 06 23;585(12). <https://doi.org/10.1016/j.febslet.2011.04.051>
 85. Jeong Hw, Hsu Kc, Lee Jw, Ham M, Ham JY, Shin HJ, Kim WS, Kim JB. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. *American journal of physiology. Endocrinology and metabolism*. 2009 04;296(4). <https://doi.org/10.1152/ajpendo.90599.2008>
 86. Wullschlegel S, Loewith R, Hall MN. TOR signaling in growth and metabolism. *Cell*. 2006 02 10;124(3). <https://doi.org/10.1016/j.cell.2006.01.016>
 87. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. *Molecular cell*. 2005 04 29;18(3). <https://doi.org/10.1016/j.molcel.2005.03.027>
 88. Leclerc I, Lenzner C, Gourdon L, Vaultont S, Kahn A, Violette Bt. Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. *Diabetes*. 2001 07;50(7). <https://doi.org/10.2337/diabetes.50.7.1515>
 89. Kawaguchi T, Osatomi K, Yamashita H, Kabashima T, Uyeda K. Mechanism for fatty acid "sparing" effect on glucose-induced transcription: regulation of carbohydrate-responsive element-binding protein by AMP-activated protein kinase. *The Journal of biological chemistry*. 2002 02 08;277(6). <https://doi.org/10.1074/jbc.M107895200>
 90. Liang J, Shao SH, Xu Z-X, Hennessy B, Ding Z, Larrea M, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. *Nature cell biology*. 2007 02;9(2). <https://doi.org/10.1038/ncb1537>
 91. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. *Nature*. 2013 01 17;493(7432). <https://doi.org/10.1038/nature11862>
 92. Steinberg GR, Hardie DG. New insights into activation and function of the AMPK. *Nature reviews. Molecular cell biology*. 2023 04;24(4). <https://doi.org/10.1038/s41580-022-00547-x>
 93. Spaulding HR, Yan Z. AMPK and the Adaptation to Exercise. *Annual review of physiology*. 2022 02 10;84. <https://doi.org/10.1146/annurev-physiol-060721-095517>
 94. Jang YJ, Byun S. Molecular targets of exercise mimetics and their natural activators. *BMB reports*. 2021 Dec;54(12). <https://doi.org/10.5483/BMBRep.2021.54.12.151>
 95. Ravel-Chapuis A, Duchesne E, Jasmin BJ. Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients. *The Journal of physiology*. 2022 07;600(14). <https://doi.org/10.1113/JP282725>
 96. Campos JC, Marchesi Bozi LH, Krum B, Grassmann Bechara LR, Ferreira ND, Arini GS, et al. Exercise preserves physical fitness during aging through AMPK and mitochondrial dynamics. *Proceedings of the National Academy of Sciences of the United States of America*. 2023 01 10;120(2). <https://doi.org/10.1073/pnas.2204750120>
 97. Richter EA, Ruderman NB. AMPK and the biochemistry of exercise: implications for human health and disease. *The Biochemical journal*. 2009 03 01;418(2). <https://doi.org/10.1042/BJ20082055>
 98. Agostini D, Natalucci V, Baldelli G, De Santi M, Donati Zeppa S, Vallorani L, et al. New Insights into the Role of Exercise in Inhibiting mTOR Signaling in Triple-Negative Breast Cancer. *Oxidative medicine and cellular longevity*.

- 2018 09 30;2018. <https://doi.org/10.1155/2018/5896786>
99. Feng L, Li B, Xi Y, Cai M, Tian Z. Aerobic exercise and resistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction. *American journal of physiology. Cell physiology*. 2022 02 01;322(2). <https://doi.org/10.1152/ajpcell.00344.2021>
100. Tao R, Gong J, Luo X, Zang M, Guo W, Wen R, et al. AMPK exerts dual regulatory effects on the PI3K pathway. *Journal of molecular signaling*. 2010 02 18;5(1). <https://doi.org/10.1186/1750-2187-5-1>
101. Zhang D, Lu C, Sang K. Exercise as a Metabolic Regulator: Targeting AMPK/mTOR-Autophagy Crosstalk to Counteract Sarcopenic Obesity. *Aging and disease*. 2025 06 07. <https://doi.org/10.14336/AD.2025.0419>
102. Tero-Vescan A, Degens H, Matsakas A, Ștefănescu R, Ösz BE, M M. Exercise-Induced Muscle-Fat Crosstalk: Molecular Mediators and Their Pharmacological Modulation for the Maintenance of Metabolic Flexibility in Aging. *Pharmaceuticals (Basel, Switzerland)*. 2025 08 19;18(8). <https://doi.org/10.3390/ph18081222>



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.